Table 1.
Subject demographics, neuropsychological, and clinical data
| Control (n = 102) | PMC (n = 40) | SMC (n = 30) | P value PMC vs. Control | P value SMC vs. PMC | |
|---|---|---|---|---|---|
| Age (years) | 44.4 (12.6) | 36.3 (15.7) | 50.5 (9.4) | 0.002** | < 0.001*** |
| Sex (male/female) | 37/65 | 14/26 | 18/12 | 0.887 | 0.038# |
| Education (years) | 11.0 (5.3) | 12.1 (4.1) | 10.5 (4.2) | 0.249 | 0.118 |
| EYO (years) | N/A | −11.6 (13.2) | 4.1 (3.1) | < 0.001*** | |
| MMSE | 29.0 (1.6) | 28.8 (1.8) | 16.5 (8.0) | 0.498 | < 0.001*** |
| MoCA | 27.1 (2.3) | 27.1 (3.0) | 12.7 (7.7) | 0.872 | < 0.001*** |
| CDR | N/A | N/A | 1.3 (0.8) | ||
| Subject numbers | |||||
| APP/PS1/PS2 | N/A | 17/21/2 | 9/18/3 | 0.474 | |
| APOEε4 (Y/N) | 26/76 | 8/32 | 10/20 | 0.490 | 0.207 |
| T1 MRI after PP | 95 | 40 | 28 | ||
| DTI after QC+PP | 45 | 24 | 9 | ||
| rsfMRI after QC+PP | 84 | 30 | 19 | ||
For continuous variables, data are shown in mean (SD), and the independent sample t-test was used for group comparison; for categorical variables, the chi-square test was used for group comparison. Bonferroni correction was used to correct for multiple comparison. #0.025 < P < 0.05, **0.001 < P < 0.01, ***P < 0.001
Y/N the number of subjects carrying (Y) or not carrying (N) APOEε4, PP preprocessing, QC quality control, PMC presymptomatic mutation carriers, SMC symptomatic mutation carriers, EYO estimated years from symptom onset, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment, CDR Clinical Dementia Rating scale